Pheochromocytoma classification

Jump to navigation Jump to search

Pheochromocytoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Pheochromocytoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Pheochromocytoma classification On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Pheochromocytoma classification

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Pheochromocytoma classification

CDC on Pheochromocytoma classification

Pheochromocytoma classification in the news

Blogs on Pheochromocytoma classification

Directions to Hospitals Treating Pheochromocytoma

Risk calculators and risk factors for Pheochromocytoma classification

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmad Al Maradni, M.D. [2]

Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.

Overview

Pheochromocytoma can be either benign or malignant and can be localized, regional, or metastatic.

Classification

Pheochromocytoma can be either benign or malignant: Malignant and benign tumours are the same on biochemical and histological bases. The only difference is the ability of the malignant one to invade local and distatant tissues (pathology and Genetics of Tumours of the Endocrine Organs. WHO Classification of Tumours, DeLellis RA, Lloyd RV, Heitz PU, Eng C. (Eds), IARC press, Lyon, France 2004). So, most cases need follow up for long durations. 10% of pheochromocytomas are malignant.

Pheochromocytomas can be localized, regional, or metastatic. 95 *% of pheochromocytomas are in the abdomen, 85 to 90 % are intraadrenal and 5 to 10 percent are multiple, 10% are extraadrenal and are referred to as catecholamine-secreting paragangliomas.

Pheochromocytoma can be either familial,non-familial or sporadic:

  • Familial paraganglioma is an autosomal dominant disorder characterized by skull, neck, thorax, abdomen and urinary bladder.
  • Non-familial pheochromocytomas include cholelithiasis, renal artery stenosis, (gastrointestinal stromal tumor [GIST], paraganglioma, adrenal cortical adenoma
  • Sporadic: Most catecholamine-secreting tumors are sporadic.

Pheochromocytoma can be classified on genetic basis into cluster 1 and cluster 2 :

References


Template:WikiDoc Sources